Hydroxyurea has been used for many years to reduce the frequency of sickle cell crisis. It has been shown to reduce vaso-occlusive crisis in patients with sickle cell anemia.
L-glutamine (Endari) is an oral powder approved to reduce oxidative stress and acute complications from sickle cell disease. One trial demonstrated a reduction in the number of hospitalizations and in the number of pain crises in patients treated with Endari.
Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018;379(3):226–235. doi:10.1056/NEJMoa1715971
Niihara Y, Macan H, Eckman JR, Koh H, Cooper ML, et al. (2014) L-Glutamine Therapy Reduces Hospitalization for Sickle Cell Anemia and Sickle β°-Thalassemia Patients at Six Months – A Phase II Randomized Trial. Clin Pharmacol Biopharm 3:116. doi:10.4172/2167-065X.1000116
L-glutamine (Endari) is an oral powder approved to reduce oxidative stress and acute complications from sickle cell disease. One trial demonstrated a reduction in the number of hospitalizations and in the number of pain crises in patients treated with Endari.
Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018;379(3):226–235. doi:10.1056/NEJMoa1715971
Niihara Y, Macan H, Eckman JR, Koh H, Cooper ML, et al. (2014) L-Glutamine Therapy Reduces Hospitalization for Sickle Cell Anemia and Sickle β°-Thalassemia Patients at Six Months – A Phase II Randomized Trial. Clin Pharmacol Biopharm 3:116. doi:10.4172/2167-065X.1000116
